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Antimicrobial resistance is currently the greatest challenge to
the effective treatment of infections globally.  Resistance
adversely affects both clinical and financial therapeutic
outcomes, with effects ranging from the failure of an individual
patient to respond to therapy and the need for expensive
and/or toxic alternative drugs to the social costs of higher
morbidity and mortality rates, longer duration of
hospitalisation, and the need for changes in empirical
therapy.1,2
It is generally accepted that antimicrobial consumption in a
population is one of the main driving forces for the
development of resistance. Several epidemiological studies
have shown that the type and frequency of resistance
mechanisms varies in different settings and such differences
have been related to qualitative and quantitative differences in
antibiotic use.3-5
We investigated the association between antibiotic use and
resistance in public-sector hospitals in KwaZulu-Natal. 
Materials and methods
Setting  
Since 1998 referral in the South African public health care
system has involved three hospital levels, viz. district, regional
and tertiary, with services ranging progressively from general
medical services to highly specialised care. KwaZulu-Natal has
2 tertiary, 9 regional and 35 district hospitals.  The study
included both tertiary, all 9 regional and 5 randomly chosen
but geographically representative district hospitals (Fig. 1).
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Objective. To investigate a possible association between level of
care, antibiotic use and antimicrobial resistance in 16 public-
sector hospitals providing different levels of care in KwaZulu-
Natal.
Design.  A multicentre surveillance study was undertaken in 16
hospitals at three progressive levels of health care (district,
regional, tertiary) where each hospital submitted 100
consecutive, non-repetitive isolates judged in the laboratory to
be of potential clinical significance.  Isolates were identified
and susceptibility testing was undertaken using the Kirby-
Bauer disc diffusion method with minimum inhibitory
concentrations (MICs) extrapolated on an automated reading
system.  Isolates were grouped according to their natural
resistance profiles, and percentage susceptibility, mean
percentage susceptibility and standard deviation to each
antibiotic were stratified within and across hospital levels.
Antibiotic use data were expressed as the number of daily
divided doses (DDDs) per 1 000 patient-days.
Setting. Two tertiary, 9 regional and 5 district public hospitals
in KwaZulu-Natal.  
Outcome measures.  Percentage susceptibility.
Results.  There was a general trend among the 1 270 isolates of
highest susceptibility in district hospitals, followed by regional
and then tertiary hospitals. This is consistent with the referral
system where health conditions become increasingly
severe/complex requiring greater antibiotic use and broader-
spectrum agents at progressive hospital levels, with statistical
significance (p < 0.05) evident where sample numbers were
relatively large.  Trend variations could be associated with the
qualitative and quantitative differences in antibiotic use, albeit
without statistical corroboration.  Three per cent of the total
number of isolates were sensitive to all antibiotics tested and
6% were resistant to a single agent only.  The remaining 91%
showed acquired resistance to more than one drug. The
standard deviation ranged from 0% to 55%.
Conclusions. This study showed that resistance profiles among
bacteria varied greatly within and across hospital levels.  While
antibiotic use varied as much, a statistically significant
correlation between use and resistance could not be
established.  It was therefore postulated that the effect of
selection pressure was obscured by other resistance
determinants apparent in public hospitals in resource-poor
settings.  On a clinical level, the study showed that resistance
profiles among bacteria vary too much to allow a national
antibiotic policy as proposed in the standard treatment
guidelines. Rather, such guidelines should be directed to
specific profiles found in different hospitals and at different
levels of health care. Regular surveillance to adjust such
guidelines is essential. 
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The microbiology laboratory at each of the 16 hospitals was
requested to submit a maximum of 100 consecutive, non-
repetitive isolates during the study period. All isolates were
considered by the laboratory staff to be of potential clinical
significance based on specimen type and clinical information.
Antibiotics
The antibiotic test panel for Gram-negative organisms included
ampicillin, amoxicillin-clavulanate, piperacillin, piperacillin-
tazobactam, cephalothin, cefuroxime, cefotaxime, ceftazidime,
cefepime, cefoxitin, meropenem, gentamicin, amikacin,
nalidixic acid, ciprofloxacin, chloramphenicol, cotrimoxazole
and nitrofurantoin.  Benzylpenicillin, ampicillin, amoxicillin-
clavulanate, oxacillin, cephalothin, cefepime, amikacin,
chloramphenicol, clindamycin, cotrimoxazole, erythromycin
and vancomycin made up the test panel for Gram-positive
organisms.
Identification
Identification methods included standard in-house laboratory
procedures6 for Gram-positive isolates and the applicable API
(bioMérieux sa, Lyon, France) systems for Gram-negatives. 
Susceptibility testing
Susceptibility testing was performed using the Kirby-Bauer
agar diffusion method following the National Committee for
Clinical Laboratory Standards (NCCLS) guidelines.7 Discs were
obtained from Mast Diagnostics, Merseyside, UK. Minimum
inhibitory concentrations (MICs) were extrapolated using the
BIOMIC automated reading system and software (Giles
Scientific, New York).  MICs were confirmed using the agar
dilution method on a selected sample.7 Methicillin-resistant
staphylococci (MRSA) were detected by means of oxacillin
screening plates (6 µg/ml of oxacillin plus 2% NaCl in Mueller
Hinton agar) and confirmed using the E-test.8
Extended-spectrum β-lactamases (ESBLs) were detected
using the double-disc test,9 while cefoxitin resistance was
presumed to be indicative of ampC production.
All tests were performed in the laboratories of the
Department of Medical Microbiology of the Nelson R Mandela
School of Medicine, which participates in the UK National
External Quality Assessment Scheme for Microbiology
(NEQAS).
Susceptibility data analysis
NCCLS breakpoints for resistance were used to differentiate
between susceptibility and resistance. Each organism was
categorised as susceptible or resistant for drugs potentially
relevant for treatment of infections with such species.  Isolates
were grouped according to their natural resistance profiles, and
percentage sensitivity to each antibiotic was stratified
according to hospital level.  The mean percentage sensitivity
and standard deviation (SD) were determined within hospital
levels.  Percentage susceptibility for each drug was also
calculated by combining all species but excluding those with
inherent resistance to a particular drug.
Antibiotic use data
Antibiotic use data were obtained from hospital pharmacy
records and expressed as usage density rate. The total number
of grams of each antibiotic used was divided by the number of
grams per daily dose for the specific antibiotic, then divided by
the patient-days, and multiplied by 1 000 to give the number of
daily divided doses (DDDs) per 1 000 patient-days.10
Statistical methods
Categorical data were reported as per cent of specimens
examined by hospital level of care (tertiary, regional, district).
An overall chi-square test was used to compare percentages of
isolates, susceptibility and antibiotic use by subgroups.  If the
overall chi-square was significant (p < 0.05), pairwise
comparisons were explored.  Where more than one comparison
was significant, the most conservative p-value was reported.  
Analysis of variance was used to compare average
antimicrobial use and prevalence of antibiotic use.   Overall
significance was reported where the differences were not
significant. Where significant, the overall p-value was not
reported. Instead the Duncan multiple range test was used to
test pairwise comparisons.  Where multiple pairwise
comparisons were significant, the most conservative p-value
was reported. 
Comparison of sensitivity by health facilities was limited to
organisms with more than 30 specimens.  Data were analysed
using SAS V8 statistical software.
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Fig. 1. Location of hospitals that participated in the study.
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Results
The number of organisms received from the different hospital
laboratories varied from 21 to 100, resulting in a total of 1 270
isolates. Twenty-four different species were identified, viz.
Escherichia coli (24%), Staphylococcus aureus (22%), Proteus spp.
(14%), Klebsiella spp. (10%), Pseudomonas spp. (9%),
Streptococcus spp. (5%), Acinetobacter spp. (4%), Enterobacter spp.
(3%), Citrobacter spp. (2%) and Enterococcus spp. (2%).  The
remaining 5% (not shown) was made up of Aeromonas spp.,
Alcaligenes faecalis, Erwinia spp., Hafnia alvei, Haemophilus
influenzae, Kluyvera spp., Morganella morganii, Neisseria
meninigitidis, Providencia stuartii, Salmonella spp., Serratia spp.,
Shigella spp. and Stenotrophomonas maltophilia. 
Table I shows the percentage susceptibility for each drug
calculated by combining all species but excluding those with
inherent resistance to a particular drug, Table II shows
antibiotic use at the different levels of care, and Table III shows
the percentage of MRSA, ESBL-producing isolates and ampC-
producing isolates identified together with the use of
antibiotics known to select for these types of resistance.1
Three per cent (N = 40) of the total number of isolates were
sensitive to all antibiotics tested and 6% (N = 79) were resistant
to a single agent only.  The remaining 1 151 isolates were multi-
resistant.
Resistance rates could be correlated with the chronological
development within antibiotic classes,  for example, greater
resistance to the earlier agents such as the penicillins and
nalidixic acid and considerably less resistance to the newer
cephalosporins and fluoroquinolones respectively.
A trend of highest sensitivity in district hospitals followed by
regional and then tertiary hospitals was evident in 58% of the
susceptibility test results, while 38% depicted the opposite
trend, i.e. highest sensitivity in tertiary hospitals followed by
regional and then district, and 6% showed no trend.  The first
trend was consistent with the referral system where health
conditions become increasingly severe/complex requiring both
greater antibiotic use and broader-spectrum agents at different
hospital levels.  However, this was only borne out in 42% of the
antibiotics, specifically broader-spectrum drugs such as
piperacillin, piperacillin-tazobactam, cefotaxime, cefoxitin,
amikacin, nitrofurantoin and vancomycin, albeit the majority
without reaching statistical significance (Table II).  Further,
although graphical representations of use and resistance
depicted negative associations in some instances, they did not
reach statistical significance. 
Table I. Antimicrobial susceptibility (%) for each drug calculated by combining all species but excluding those with inherent
resistance to a particular drug for different levels of hospital-based health care*
Hospital level
District Regional Tertiary
Antibiotic N % N % N % p-value†
Penicillin G 118 18 185 20 34 12 0.5
Ampicillin 335 22 416 22 133 27 0.4
Amoxicillin-clavulanate 379 53 504 53 165 48 0.6
Piperacillin 284 46 386 54 129 45 0.07
Piperacillin-tazobactam 284 89 386 88 129 73 < 0.0001
Oxacillin 102 83 145 72 30 77 0.2
Cephalothin 379 60 504 57 165 42 < 0.0001
Cefuroxime 250 52 315 49 119 35 0.008
Cefotaxime 284 84 386 71 129 66 < 0.0001
Ceftazidime 284 98 386 91 129 82 < 0.0001
Cefepime 444 93 619 89 191 81 < 0.0001
Cefoxitin 315 78 430 67 145 66 0.002
Meropenem 315 100 430 99 145 98 0.03
Gentamicin 315 89 430 82 145 70 < 0.0001
Amikacin 417 97 575 91 175 76 < 0.0001
Chloramphenicol 444 63 619 64 191 56 < 0.0001
Naladixic acid 281 70 359 64 135 47 0.003
Ciprofloxacin 315 91 430 87 145 80 0.2
Nitrofurantoin 281 58 359 55 135 47 0.1
Trimethoprim-
sulphamethoxazole 444 48 619 46 191 43 0.5
Erythromycin 118 65 185 66 34 59 < 0.001
Clindamycin 129 74 189 76 46 59 0.06
Vancomycin 129 100 189 100 46 100 NA





The large SD values ranging from 0%
to 55% emphasised susceptibility
differences between hospitals within
district, regional and tertiary levels. 
When all isolates were combined in
Table I, significantly lower levels of
susceptibility were found in isolates
from tertiary care hospitals for
piperacillin-tazobactam (p < 0.0001) but
not for piperacillin. There were also
significantly lower levels of
susceptibility for the different
generations of cephalosporins 
(p < 0.0001 to p = 0.008). This was
accompanied by a higher number of
ESBL-producing K. pneumoniae isolates
at this hospital level (Table I). However,
when all ESBL-selecting β-lactams were
combined no significant differences in
use were found (Table III). 
Resistance to cefoxitin was
significantly higher in both regional and
tertiary hospitals as compared with
district hospitals (p = 0.01) (Table I). This
was accompanied by a similar
distribution of ampC-producing
organisms but not with use of ampC-
selecting drugs (Table III). 
The remaining significant findings in
difference in susceptibility (gentamicin,
amikacin, meropenem and clindamycin)
were all between tertiary and both the
other levels of care, with higher
resistance in the former (Table I). This
corresponded with higher antibiotic use
in the tertiary institutions for
meropenem (p = 0.4) and amikacin (p =
0.03). However, use of clindamycin was
similar at both tertiary and regional
levels while use of gentamicin was
highest at district level (p = 0.02) 
(Table II).
There was a difference in the use of
MRSA-selecting antibiotics between
district hospitals and both other levels
of care. The percentage of MRSA among
the S. aureus isolates followed this trend
but this did not reach statistical
significance (Table III).
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Table II. Average antimicrobial use (DDD/1 000 patient-days) from different levels
of hospital-based health care
Antibiotic District Regional Tertiary p-value
Penicillin G 371.17 430.44 565.364 0.7
Ampicillin 0.028 0.034 0.01 0.6
Amoxicillin-
clavulanate 0.025 0.152 0.09 0.2
Piperacillin 0 0.001 0.001 0.3
Piperacillin-
tazobactam 0 0.005 0.008 0.009 (T = R) > D
p < 0.05
Cloxacillin 0.026 0.04 0.029 0.6
First cephalosporins 
(cefazolin, cephradine) 0.054 0.176 0.069 0.3 (R = T) p = 0.6 
and T > D p < 0.05
Cefuroxime 0.015 0.39 0.046 0.054
Cefotaxime 0.006 0.012 0.01 0.5
Ceftazidime 0 0.001 0 0.7
Ceftriaxone 0.024 0.018 0.032 0.8
Cefepime 0 0 0 0
Cefoxitin 0 0.009 0.018 0.01 T > D p < 0.05
Meropenem 0 0 0.001 0.4
Gentamicin 0.088 0.001 0.001 0.02 D > R = T
Amikacin 0 0.006 0.009 0.03 T > D
Chloramphenicol 0.007 0.007 0.002 0.5
Naladixic acid 0.248 0.065 0.009 0.2
Ciprofloxacin 0.071 0.056 0.035 0.5
Nitrofurantoin 0.008 0.011 0.094 3E-04 T > (R = D)
Trimethoprim-
sulphamethoxazole 1.299 2.052 0.642 0.3
Erythromycin 0.614 0.681 0.096
Clindamycin 0 0.004 0.003 0.08
Vancomycin 0 0.002 0.003 0.2
Total use 2 978.3 2 764.98 1 091.88
Analysis of variance  (ANOVA) was used to test overall significance, which is reported if non-significant. Where
significant, it is not reported. The Duncan multiple range test was used to test pairwise comparisons.  Where multiple
comparisons are significant, the most conservative p-value is reported.
DDD = daily divided dose. 
Table III. Percentage MRSA, ESBL-producing isolates and ampC-producing isolates
and use of antibiotics* selecting resistance
Hospital level
District Regional Tertiary p-value
MRSA 17 28 23 0.15¶
MRSA-selecting β-lactam use† 0.151 0.449 0.296 0.05|| R > D
ESBL-producing organisms 1 3 9 0.001¶
ESBL-selecting β-lactam use‡ 0.1 0.251 0.168 0.13||
Gentamicin use 0.088 0.001 0.001 0.02|| D > R = T
AmpC-producing organisms 22 33 34 < 0.002¶
Cefoxitin use 0 0.009 0.018 0.2||
AmpC-selecting β-lactam use§ 0.031 0.04 0.06 0.5||
*Average daily divided dose/1 000-patient days.
†Cloxacillin, all cephalosporins and penicillin-inhibitor combinations.
‡All cephalosporins.
§All 1st, 2nd and 3rd generation cephalosporins.
¶Chi square/exact test.
||Analysis of variance (ANOVA) was used to test overall significance which is reported if non-significant. Where
significant, it is not reported. The Duncan multiple range test was used to test pairwise comparisons.  Where multiple
comparisons are significant, the most conservative p-value is reported.
MRSA = methicillin-resistant Staphylococous aureus; ESBL = extended-spectrum β-lactamase.
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Discussion
This study reports on resistance patterns among potentially
clinically significant isolates of bacteria from hospitalised
patients at different levels of health care and relates this to
antibiotic selective pressure. A general trend of highest
susceptibility in isolates from district hospitals followed by
those from regional and then tertiary hospitals was evident and
this is consistent with the referral system where health
conditions become increasingly severe/complex requiring both
greater antibiotic use and broader-spectrum agents at different
hospital levels.  
When use and prevalence of resistance were compared for
individual antibiotics, differences in levels of resistance were
found for 13 (57%) of the 23 antimicrobials tested (Table I).
However, significant differences in amounts used were found
with only 3 (13%) of these drugs (Table II). In only 1 of these
(amikacin), resistance levels increased with use. Time-wise,
resistance should follow increased use. This lack of correlation
may be attributed to the fact that use data were collected in the
same period as the resistance data. However, this was believed
to be an unlikely explanation because the same antimicrobial
policies have been in place for many years in both regional and
tertiary care hospitals.  
The three significant associations found were between
piperacillin-tazobactam use and ESBL producers, between
cefoxitin use and ampC producers, and between amikacin use
and amikacin resistance. In tertiary hospitals, piperacillin-
tazobactam is successfully used as first-line agent for the
treatment of infections with ESBL-producing organisms.11
Therefore, despite its association with the prevalence of ESBL
producers, it is unlikely that this drug is the selective agent for
these organisms. Despite the fact that in our environment ESBL
production is associated with gentamicin resistance,12 the
association between use of this drug and ESBL prevalence was
a negative one (Table III). Although this did not reach statistical
significance, the higher use of the cephalosporins in regional
and tertiary hospitals is therefore the most likely explanation
for the higher prevalence of ESBL-producing organisms in
these hospitals compared with the district hospitals.
Cefoxitin is used for surgical prophylaxis. The use pattern
reflects the fact that most surgery for which prophylaxis is
indicated takes place in the higher-level hospitals. This might
explain the higher prevalence of ampC-carrying organisms
(Table III) and cefoxitin resistance (Table I).
Because of the high prevalence of ESBL producers (Table III)
also exhibiting gentamicin resistance in our environment, the
first-line aminoglycoside in regional as well as tertiary
hospitals is amikacin. This explains the high level of amikacin
resistance (Table I) in these hospitals and the negative
association between gentamicin use and ESBL producers (Table
III). 
Selection of resistance to one particular antibiotic is not the
result of use of the drug in question only, but also use of all
related drugs. Therefore, we looked at associations between the
prevalence of resistant organisms and use of categories of
selective antimicrobials (Table III). Here we found an
association between β-lactam use and the prevalence of MRSA.
Associations between ESBL-producing organisms, ampC
carriers and the use of their respective selective drug categories
were not found. 
Like others,5,13-15 we found that the association between drug
use and resistance patterns is not straightforward.  Factors such
as infection control, hospital level, ward type, patient and
disease profiles, invasive procedures and staffing have all been
reported as confounders.  More recently, the mechanisms by
which antibiotics select resistance in bacteria (mutation versus
acquisition of resistance genes) have also been quoted in this
context.13,14
While this multicentre study clearly established the
prevalence of high levels of resistance in certain hospitals, a
limitation of the study was that the data could not be
correlated with clinical outcome and did not inform potential
strategies, partly because a multiplicity of factors impacts on
antibiotic resistance in hospital settings.  Resistance may
emerge by selection pressure (overuse/indiscriminate
antimicrobial use in developed versus underuse/misuse in
developing countries) but is perpetuated by diverse risk factors
and maintained within environments as a result of poor
infection control.   Population-specific drug pharmacokinetics
and pharmacodynamics also play a role.   
This study showed that associations between use of
antimicrobials and resistance patterns in bacteria do exist but
proof of a direct causal relationship is constrained by several
confounding factors. Studies that take those confounders into
account are needed. 
On a clinical level, the study showed that resistance profiles
among bacteria vary too much to allow a national antibiotic
policy as proposed in the standard treatment guidelines.
Rather; such guidelines should be directed to specific profiles
found in different hospitals and at different levels of health
care. Regular surveillance to adjust such guidelines is essential. 
A way forward would be to institute a surveillance
programme which should be disease-based, establishing
sensitivity profiles of common causative organisms to inform
the development of or amendment to standard treatment
guidelines and essential drugs lists adopted within national
drug policies in developing countries globally.  The manner of
antimicrobial use (overuse, underuse, inadequate dosing)
associated with resistance must be established for appropriate
intervention in terms of rational drug use, a reduction in use
and dosing regimens based on population-specific
pharmacokinetics and pharmacodynamics.  Risk factors unique
to South African communities (poverty, HIV and AIDS) 
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and hospitals (duration of hospitalisation, location within the
hospital, intensive care unit stay, surgery, wounds, previous
and current antimicrobial therapy, mechanical ventilation,
urinary catherterisation, nasogastric intubation, central venous
and peripheral catheters, previous hospitalisation, transfer
from another unit or hospital, etc.) must be determined and
due vigilance exercised in patients exhibiting classic risk factors
for the acquisition of or colonisation with resistant pathogens.
Hygiene and sanitation (in communities) and infection control
(in hospitals) status must be determined and interventions
initiated to prevent the spread of resistance.  Pharmacokinetics
and pharmacodynamics specific to diverse populations must
be devised to optimise antimicrobial therapy.  
South Africa has unique needs in the antimicrobial resistance
arena, needs to be addressed in the context of severe financial,
human-resource and technological challenges. 
Detailed results on species distribution at the different levels of
hospital-based care, percentage susceptibility per species and mean
percentage susceptibility and SD within hospital levels are
available on request from the corresponding author.
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